WO2002018001A2 - Appareil permettant le traitement d'une maladie pulmonaire avec obstruction chronique et procede associe - Google Patents
Appareil permettant le traitement d'une maladie pulmonaire avec obstruction chronique et procede associe Download PDFInfo
- Publication number
- WO2002018001A2 WO2002018001A2 PCT/US2001/026939 US0126939W WO0218001A2 WO 2002018001 A2 WO2002018001 A2 WO 2002018001A2 US 0126939 W US0126939 W US 0126939W WO 0218001 A2 WO0218001 A2 WO 0218001A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- patient
- opening
- chamber
- treatment
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract description 14
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 title description 4
- 239000000203 mixture Substances 0.000 claims abstract description 42
- 239000003937 drug carrier Substances 0.000 claims abstract description 12
- 208000019693 Lung disease Diseases 0.000 claims abstract description 11
- 230000001684 chronic effect Effects 0.000 claims abstract description 11
- 206010061876 Obstruction Diseases 0.000 claims abstract description 10
- 238000002663 nebulization Methods 0.000 claims abstract description 7
- 239000012530 fluid Substances 0.000 claims abstract description 6
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 25
- 230000000241 respiratory effect Effects 0.000 claims description 22
- 239000006199 nebulizer Substances 0.000 claims description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- 239000011780 sodium chloride Substances 0.000 claims description 5
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical group [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 abstract description 6
- 206010011224 Cough Diseases 0.000 description 23
- 208000006673 asthma Diseases 0.000 description 23
- 230000011514 reflex Effects 0.000 description 15
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 12
- 235000002906 tartaric acid Nutrition 0.000 description 12
- 239000011975 tartaric acid Substances 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 230000009325 pulmonary function Effects 0.000 description 8
- 238000009613 pulmonary function test Methods 0.000 description 7
- 238000001629 sign test Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000003434 inspiratory effect Effects 0.000 description 6
- 230000002411 adverse Effects 0.000 description 5
- 206010006482 Bronchospasm Diseases 0.000 description 4
- 210000003097 mucus Anatomy 0.000 description 4
- 239000002253 acid Substances 0.000 description 3
- 230000007885 bronchoconstriction Effects 0.000 description 3
- 230000007883 bronchodilation Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 230000004043 responsiveness Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 210000001170 unmyelinated nerve fiber Anatomy 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 2
- 206010047141 Vasodilatation Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000000528 statistical test Methods 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 101100476210 Caenorhabditis elegans rnt-1 gene Proteins 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 206010020591 Hypercapnia Diseases 0.000 description 1
- 206010021079 Hypopnoea Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 206010035669 Pneumonia aspiration Diseases 0.000 description 1
- 102100024304 Protachykinin-1 Human genes 0.000 description 1
- 206010048979 Sinobronchitis Diseases 0.000 description 1
- 101800003906 Substance P Proteins 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 210000003489 abdominal muscle Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000008371 airway function Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000008784 apnea Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 201000009807 aspiration pneumonia Diseases 0.000 description 1
- 150000001552 barium Chemical class 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 108091008690 chemoreceptors Proteins 0.000 description 1
- 208000023819 chronic asthma Diseases 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 208000000122 hyperventilation Diseases 0.000 description 1
- 230000000870 hyperventilation Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 210000000876 intercostal muscle Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000004393 laryngeal mucosa Anatomy 0.000 description 1
- 210000003801 laryngeal nerve Anatomy 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 1
- 229960002329 methacholine Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 230000001007 puffing effect Effects 0.000 description 1
- 210000003456 pulmonary alveoli Anatomy 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000036389 reflex bronchoconstriction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0021—Mouthpieces therefor
- A61M15/0023—Mouthpieces therefor retractable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2209/00—Ancillary equipment
- A61M2209/06—Packaging for specific medical equipment
Definitions
- the present invention relates to the medical field, and more particularly to a treatment for a pulmonary disease involving chronic obstruction of the airways, to a nebulizer apparatus for delivery of the medication, and to a treatment kit therefor.
- references Cited 1. Addington WR, Stephens RE, Gflliland K, Rodriguez . Assessing the laryngeal cough reflex and the risk of developing pneumonia after stroke. Arch Phys ed Rehabil. 1999;80:150-4. 2. Addington WR, Stephens RE, Gilliland KA. Assessing the laryngeal cough reflex and the risk of developing pneumonia after stroke: an interhospital comparison. Stroke. 1999;30: 1203-7. 3. Tomori Z, Stransky A. Electroneurographic and pneumotachographic analysis of the expiration reflex. Physiol Bohemoslov. 1973;22:589-601. 4. Fujimura M, Sakamoto S, Kamio Y, Matsuda T. Cough receptor sensitivity and bronchial responsiveness in normal and asthmatic subjects. Eur Respir J. 1992;5:291-5.
- Widdicombe JG Reflexes from the upper respiratory tract. Bethesda, MD: The American Physiological Society; 1986.
- Widdicombe JG Afferent receptors in the airways and cough. Respir Physiol. 1998 Oct; 114:5-15.
- Widdicombe J Airway receptors. Respir Physiol. 2001;125:3-15. 17. Widdicombe JG. Chemoreceptor control of airways. Respir Physiol.
- the laryngeal cough reflex (LCR) and its precursor, the laryngeal cough expiratory reflex (LCER), are primal, brainstem mediated reflexes that have been shown in humans to protect the upper airway from the aspiration of potentially harmful material into the lungs.
- the LCER when stimulated via the inhalation of a nebulized composition of tartaric acid, triggers a cascade of neurological events which ultimately results in the contraction of the abdominal and intercostal muscles to produce an initial expiration in an attempt to clear the abnormal aspirant. This is followed by a series of more forceful coughs with inspiratory and expiratory components (LCRs).
- the present invention advantageously provides a nebulizer apparatus for treatment of a patient having a pulmonary disease involving chronic obstruction of the airways.
- the apparatus is adapted for self-treatment by the patient, and comprises a container sized to be portable by the patient and having therein a chamber containing a composition comprising a pharmaceutically acceptable carrier mixed with L-tartaric acid.
- a nebulizing valve having an opening connected to the chamber is positioned so as to provide an outlet therefor, and a source of motivating force connected with the chamber so as to motivate the composition through the opening in the nebulizing valve to thereby cause nebulization of the composition.
- nebulization comprises droplets having an airborne diameter of less than about 10 ⁇ m, and the L-tartaric acid is mixed in the composition in an amount effective for causing an increase in peak respiratory flow when inhaled by the patient.
- the invention also includes a method for treatment of a patient having a pulmonary disease involving chronic obstruction of the airways.
- the method comprises inhalation by the patient of a nebulized composition comprising a pharmaceutically acceptable carrier mixed with L-tartaric acid in an amount effective for causing an increase in peak respiratory flow.
- the pharmaceutically acceptable carrier preferably comprises a solution having at least about 0.15 M sodium chloride, and at least about 20% L- tartrate.
- a treatment kit is adapted for self-treatment by a patient having a pulmonary disease involving chronic obstruction of the airways.
- the kit comprises a container sized to be portable by the patient, and containing a pharmaceutically acceptable carrier mixed with L-tartaric acid in an amount effective for causing an increase in peak respiratory flow when inhaled by the patient, a nebulizing valve connected to the chamber, and a source of pneumatic pressure to motivate the composition through the valve to thereby generate a nebulized composition comprising droplets having an airborne diameter of less than about 10 ⁇ m.
- the kit also includes a generally tubular mouthpiece connectable to the container so as to be in fluid connection with the nebulizing valve to convey the nebulized composition into a patient's mouth for oral inhalation by the patient.
- the kit may also comprise a removable cap fitting over the mouthpiece, a nose clip to aid the patient in oral inhalation of the composition, and a respiratory flow meter for determining increase in peak respiratory flow.
- FIG. 1 is a flow diagram illustrating a treatment method according to an embodiment of the present invention
- FIG. 2 shows the nebulizer apparatus of the present invention in use
- FIG. 3 is a top plan view of a kit comprising the described invention for self-treatment by a patient.
- the RCT stimulates cough receptors in the vestibule of the larynx and initiates the LCER/LCR.[4,5,8-10]
- the RCT (Pneumoflex Systems, Inc., Orlando, FL) was performed by administering to the subjects a composition comprising a 20% solution of pharmaceutical grade L-tartaric acid dissolved in sterile 0.15 M NaCI solution, and inhaled from a Bennett Twin nebulizer. During the inhalation, the subject's nose was pinched closed. The nebulizer output was approximately 0.2 ml/min. [1,2,4-6,8, 10] The subjects were tested in the standing position for all PFT and RCT tests. Subjects were tested for two effective inhalations.
- the subject was asked to exhale, then insert the mouthpiece, and take a sharp, deep inhalation. Leakage around the mouthpiece and "puffing" the nebulizer were not considered effective inhalations.
- the respiratory therapist used a Spiromate AS-600 for all PFTs (SN6546, Riko Medical and Scientific Corporation Instruments).
- FEV1/FVC Pre . RCT
- FEV1/FVC Post _ 5 RCT
- the mean age of the normal and asthmatic subjects was 36.85 ⁇ 8.62 (S.D.), and 66.20 ⁇ 13.13, respectively. All subjects had a normal ⁇ reflex response to RCT, consisting of LCER efforts followed by the LCR without adverse effects.
- Table 3 shows that for each of the ten investigated variables, the normal group always had greater mean values than did the asthma group.
- nasopharyngeal mucosa causes bronchodilatation [11], but the receptors for this reflex are not very chemosensitive and the associated respiratory changes are not expiration or cough but are inspiratory efforts (the aspiration reflex). Based on this, it would appear that nasopharyngeal reflexes are unlikely to mediate any bronchodilatation after the RCT.
- the laryngeal receptors for the LCER and the LCR are almost certainly rapidly adapting ("irritant") receptors (RARs), both In experimental animals [12] and in man [8], and they are stimulated by acid solutions.
- RARs rapidly adapting receptors
- C-fiber receptors in the trachea, bronchi and alveolar walls are also all stimulated by acid solutions, and while the response of laryngeal C-fiber receptors to acid does not seem to have been studied, there is no reason to believe that they behave differently from those elsewhere in the respiratory tract.
- the invention includes a method for treatment of a patient having a pulmonary disease involving chronic obstruction of the airways.
- the method comprises inhalation of a nebulized composition of L-tartrate in a pharmaceutically acceptable carrier in an amount effective for causing an increase in peak respiratory flow.
- the method starts [Block 5] with preparation of the composition [Block 7], followed by nebulization of the composition [Block 9], inhalation of the nebulized composition by the patient [Block 11], and finally by measuring the respiratory peak flow [Block 13]. Inhalation may be repeated if no increase is measured [Block 15]. If increased flow is noted, the method stops [Block 17].
- L-tartrate is preferably in a substantially soluble form in an aqueous solution of isotonic sodium chloride.
- a concentration of L-tartrate which is preferred in the present invention is about 20% L-tartrate.
- the nebulized composition preferably comprises droplets having an airborne diameter of about 10 ⁇ m or less to promote penetration into the lower respiratory airways. The composition was found to be adequately nebulized at a rate of about 0.2 ml per minute.
- the pulmonary disease comprises the group of chronic obstructive pulmonary diseases consisting of simple chronic bronchitis, asthma and asthmatic bronchitis, chronic obstructive bronchitis, emphysema, bronchiectasis, cystic fibrosis, and bronchiolitis.
- a nebulizer apparatus 20 adapted for self-treatment by a patient having a pulmonary disease involving chronic obstruction of the airways, as shown in use in FIG. 2.
- the nebulizer includes a container 22 sized to be portable by the patient and having therein a chamber containing a composition comprising a pharmaceutically acceptable carrier mixed with L-tartaric acid in an amount effective for causing an increase in peak respiratory flow when inhaled by the patient.
- a nebulizing valve having an opening is connected to the chamber so as to provide an outlet therefor.
- a source of motivating force communicates with the chamber so as to motivate the composition through the opening in the nebulizing valve to thereby cause nebulization of the composition to comprise droplets having an airborne diameter of less than about 10 ⁇ m.
- the container 22 comprises a metal cylinder
- the source of motivating force comprises pneumatic pressure, and preferably a compressed gas within the container.
- the nebulizer apparatus 20 comprises a mouthpiece 24 positioned in fluid connection with the opening and downstream therefrom to thereby convey the nebulized composition to the mouth of the patient so as to facilitate oral inhalation.
- the pharmaceutically acceptable carrier preferably comprises a solution of at least about 0.15 M sodium chloride, and is prepared with at least about 20% L-tartaric acid.
- FIG. 3 Yet another aspect of the invention, as shown in FIG. 3, includes a treatment kit 30 adapted for self-treatment by a patient having a pulmonary disease involving chronic obstruction of the airways.
- the kit 30 comprises the container 22 described above, and a mouthpiece 24 connectable to the container so as to be in fluid connection with the valve opening and downstream therefrom to thereby convey the nebulized composition into a patient's mouth to facilitate oral inhalation.
- the treatment kit advantageously may further comprise a removable cap 26 fitting over the mouthpiece 24 for protection.
- the treatment kit may include a plurality of containers thereby providing replacements, and may also include a nose clip 28, and a respiratory flow meter 32 for measuring increased peak respiratory flow.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pulmonology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Otolaryngology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
L'invention concerne un appareil et un procédé permettant le traitement d'un patient atteint d'une maladie pulmonaire avec obstruction chronique des voies aériennes. Cet appareil comporte un récipient comprenant une chambre contenant une composition de L-tartrate dans un excipient pharmaceutiquement acceptable; une ouverture pratiquée dans la chambre de manière à permettre une sortie de la composition, l'ouverture étant dimensionnée pour produire des gouttelettes d'un ordre de grandeur prédéterminé adapté à la composition qui est dirigée depuis la chambre à travers l'ouverture; et une source propulsive connectée à la chambre de façon à propulser la composition à travers l'ouverture et provoque ainsi la nébulisation de la composition. Une trousse de traitement comprend le récipient décrit ainsi qu'un embout buccal raccordable au récipient, de manière à être en connexion fluidique avec l'ouverture et permettre une projection vers l'aval, afin de transporter ainsi la composition nébulisée jusque dans la bouche d'un patient pour lui faciliter de la sorte l'inhalation orale de la composition nébulisée.
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002420545A CA2420545A1 (fr) | 2000-08-30 | 2001-08-30 | Appareil permettant le traitement d'une maladie pulmonaire avec obstruction chronique et procede associe |
| EP01968244A EP1313525A2 (fr) | 2000-08-30 | 2001-08-30 | Appareil permettant le traitement d'une maladie pulmonaire avec obstruction chronique et procede associe |
| AU8850301A AU8850301A (en) | 2000-08-30 | 2001-08-30 | Apparatus for treatment of chronic obstructive pulmonary disease and associated method |
| AU2001288503A AU2001288503B2 (en) | 2000-08-30 | 2001-08-30 | Apparatus for treatment of chronic obstructive pulmonary disease and associated method |
| MXPA03001840A MXPA03001840A (es) | 2000-08-30 | 2001-08-30 | Aparato para el tratamiento de padecimiento pulmonar obstructivo cronico y metodo asociado. |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22906600P | 2000-08-30 | 2000-08-30 | |
| US60/229,066 | 2000-08-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2002018001A2 true WO2002018001A2 (fr) | 2002-03-07 |
| WO2002018001A3 WO2002018001A3 (fr) | 2002-07-25 |
Family
ID=22859715
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2001/026939 WO2002018001A2 (fr) | 2000-08-30 | 2001-08-30 | Appareil permettant le traitement d'une maladie pulmonaire avec obstruction chronique et procede associe |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1313525A2 (fr) |
| AU (2) | AU8850301A (fr) |
| CA (1) | CA2420545A1 (fr) |
| MX (1) | MXPA03001840A (fr) |
| WO (1) | WO2002018001A2 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7992803B2 (en) | 2007-10-31 | 2011-08-09 | Stevens Medical, Llc | Nebulizer having a high efficiency impactor |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5839430A (en) * | 1996-04-26 | 1998-11-24 | Cama; Joseph | Combination inhaler and peak flow rate meter |
| CA2315777C (fr) * | 1998-01-16 | 2008-12-23 | 1263152 Ontario Inc. | Dispositif indicateur a utiliser conjointement avec un dispositif distributeur |
| SE9801077D0 (sv) * | 1998-03-27 | 1998-03-27 | Shl Medical Ab | Inhalator |
| US6004268A (en) * | 1998-04-21 | 1999-12-21 | Addington; W. Robert | Aspiration screening process for assessing post surgery patient's risk for pneumonia |
-
2001
- 2001-08-30 MX MXPA03001840A patent/MXPA03001840A/es active IP Right Grant
- 2001-08-30 AU AU8850301A patent/AU8850301A/xx active Pending
- 2001-08-30 CA CA002420545A patent/CA2420545A1/fr not_active Abandoned
- 2001-08-30 AU AU2001288503A patent/AU2001288503B2/en not_active Ceased
- 2001-08-30 EP EP01968244A patent/EP1313525A2/fr not_active Withdrawn
- 2001-08-30 WO PCT/US2001/026939 patent/WO2002018001A2/fr active IP Right Grant
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7992803B2 (en) | 2007-10-31 | 2011-08-09 | Stevens Medical, Llc | Nebulizer having a high efficiency impactor |
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA03001840A (es) | 2004-11-01 |
| EP1313525A2 (fr) | 2003-05-28 |
| AU2001288503B2 (en) | 2007-05-17 |
| CA2420545A1 (fr) | 2002-03-07 |
| AU8850301A (en) | 2002-03-13 |
| WO2002018001A3 (fr) | 2002-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tatar et al. | Laryngeal and tracheobronchial cough in anesthetized dogs | |
| Zhang et al. | Oropharyngeal leak pressure with the laryngeal mask airway Supreme™ at different intracuff pressures: a randomized controlled trial | |
| Dohna‐Schwake et al. | IPPB‐assisted coughing in neuromuscular disorders | |
| Kenia et al. | Does inhaling menthol affect nasal patency or cough? | |
| Kanniess et al. | Effect of inhaled ciclesonide on airway responsiveness to inhaled AMP, the composition of induced sputum and exhaled nitric oxide in patients with mild asthma | |
| US6679249B2 (en) | Apparatus for treatment of chronic obstructive pulmonary disease and associated method | |
| Bolser et al. | Antitussive effects of GABAB agonists in the cat and guinea‐pig | |
| Hasani et al. | Effect of aromatics on lung mucociliary clearance in patients with chronic airways obstruction | |
| Reddy et al. | Dose-dependent effectiveness of ketamine nebulisation in preventing post-operative sore throat due to tracheal intubation. | |
| Ali et al. | Ketofol performance to reduce postoperative emergence agitation in children undergoing adenotonsillectomy | |
| Kissoon et al. | Effect of β2‐agonist treatment and spirometry on exhaled nitric oxide in healthy children and children with asthma | |
| US11484509B2 (en) | Mint mask and methods of use thereof | |
| Bronsky et al. | Inspiratory flow rates and volumes with the Aerolizer dry powder inhaler in asthmatic children and adults | |
| Orji et al. | Nebulized magnesium versus ketamine for prevention of postoperative sore throat in patients for general anaesthesia | |
| AU2001288503B2 (en) | Apparatus for treatment of chronic obstructive pulmonary disease and associated method | |
| Raphael et al. | Effects of topical benzocaine and lignocaine on upper airway reflex sensitivity | |
| AU2001288503A1 (en) | Apparatus for treatment of chronic obstructive pulmonary disease and associated method | |
| Fairfield et al. | Oxygen delivery systems–A comparison of two devices | |
| Mutoh et al. | Hypersensitivity of laryngeal C-fibers induced by volatile anesthetics in young guinea pigs | |
| Addington et al. | Effect of tartaric acid–induced cough on pulmonary function in normal and asthmatic humans | |
| Hewer et al. | A prospective study of atropine premedication in flexible bronchoscopy | |
| Sarkiss | Anesthesia for interventional bronchoscopic procedures | |
| Chen et al. | Effects of inhaled lidocaine on exercise-induced asthma | |
| DEVI et al. | Comparison of Preoperative Magnesium Sulphate and Budesonide Nebulisation in Reducing the Incidence and Severity of Postoperative Sore Throat-A Randomised Controlled Study. | |
| SHARMA et al. | Comparison of Incidence of Postoperative Sore Throat after Nebulisation with Ketamine, Lignocaine and Magnesium Sulphate-A Randomised Controlled Trial. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2001288503 Country of ref document: AU |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2420545 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2003/001840 Country of ref document: MX |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2001968244 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 2001968244 Country of ref document: EP |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| NENP | Non-entry into the national phase |
Ref country code: JP |
|
| WWG | Wipo information: grant in national office |
Ref document number: 2001288503 Country of ref document: AU |